Emergent Biosolutions spent $550K lobbying in 1Q
http://www.forbes.com/feeds/ap/2008/06/27/ap5163489.html
WASHINGTON - Biopharmaceutical company Emergent BioSolutions Inc. spent $550,000 lobbying in the first quarter, according to a recent disclosure form.
Emergent BioSolutions (nyse: EBS - news - people ) lobbied on the government stockpiling of biodefense vaccines. The company holds a three-year, $448 million contract with the Department of Health and Human Services for the anthrax vaccine BioThrax.
Besides Congress, the Rockville, Md.-based company lobbied the departments of Defense and Health and Human Services, according to the form posted online April 17 by the House clerk's office.
WASHINGTON - Biopharmaceutical company Emergent BioSolutions Inc. spent $550,000 lobbying in the first quarter, according to a recent disclosure form.
Emergent BioSolutions (nyse: EBS - news - people ) lobbied on the government stockpiling of biodefense vaccines. The company holds a three-year, $448 million contract with the Department of Health and Human Services for the anthrax vaccine BioThrax.
Besides Congress, the Rockville, Md.-based company lobbied the departments of Defense and Health and Human Services, according to the form posted online April 17 by the House clerk's office.
